RecruitingPhase 3NCT05795140
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Studying Atypical hemolytic uremic syndrome with anti-factor H antibodies
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Iptcaopan 200 mg(drug)
- Enrollment
- 125 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2024 – 2033
Study locations (6)
- Novartis Investigative Site, São Paulo, São Paulo, Brazil
- Novartis Investigative Site, Rio de Janeiro, Brazil
- Novartis Investigative Site, Beijing, China
- Novartis Investigative Site, Ostrava, Poruba, Czechia
- Novartis Investigative Site, Nagpur, Maharashtra, India
- Novartis Investigative Site, Pune, Maharashtra, India
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05795140 on ClinicalTrials.gov